Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200032/S004

Occlutech ASD Occluder; Occlutech Pistol Pusher (OPP); Occlutech ASD Occluder Procedure Pack

Occlutech Holding AG · Decision date Dec 18, 2025

FDA DECISIONP200032/S004

What did the FDA decide?

FDA records P200032/S004 as a supplement to PMA P200032, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 18, 2025.

FDA approval order statement

consolidation of manufacturing operations for the Occlutech ASD Occluder by moving all remaining production activities and equipment from your 'TIP' (Technologie-und Innovationspark) facility to your 'BIZ' (Bioinstrumentezentrum) facility
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Dec 18, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P200032/S004
Regulatory pathway
PMA supplement
Product code
OZG
Decision code
OK30
Decision date
Dec 18, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Transcatheter septal occluder (atrial).

Product code
OZG
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P200032/S004 received

    Application receipt date recorded by FDA.

  2. P200032/S003 · Related supplement

    Occlutech ASD Occluder; Occlutech Pistol Pusher (OPP); Occlutech ASD Occluder Procedure Pack

  3. P200032/S004 · FDA decision

    30-Day Notice

  4. P200032/S005 · Related supplement

    Occlutech Pistol Pusher

  5. P200032/S006 · Related supplement

    Occlutech ASD Occluder and Occlutech Pistol Pusher

Timeline entries are records held by MedtechLedger for P200032. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200032

Product / regulatory recordCompanyPathwayDecision dateSource
Occlutech Holding AGPMA supplementNov 24, 2025FDA
Occlutech Holding AGPMA supplementMay 11, 2026FDA
Occlutech Holding AGPMA supplementJun 5, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Occlutech Holding AG

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Feldstrasse 22, Schaffhausen, 8200

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records